AI Article Synopsis
Article Abstract
Methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) plasma concentration-time curves (AUC) have been analyzed in 24 patients after different routes of MTX administration. After an i.v. bolus (50 mg/m2), the AUC for 7-OH-MTX is correlated with that for MTX and inversely correlated with the MTX plasma clearance. When MTX is administered with plasma steady level standardization, using the test-dose protocol, at a level of 10(-5) M over 36 hr (10(-5), 36 hr), 7-OH-MTX-AUC is still correlated with the i.v. bolus pharmacokinetic parameters. The dose prediction using the classical test-dose protocol provides a less efficient MTX dose adjustment at 5 X 10(-4) M over 8 hr (5.10(-4), 8 hr) and the hydroxylation process is no more correlated with the i.v. parameters. On the opposite, upon 6 successive infusions with 10(-5), 36 hr or 5.10(-4), 8 hr protocols, the plasma concentrations of 7-OH-MTX are not significantly modified. This suggests that the hydroxylation process is not inducible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0277-5379(87)90307-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Micronutrient dose response (MiNDR) study among women of reproductive age and pregnant women in rural Bangladesh: study protocol for double-blind, randomised, controlled trials.
BMJ Open
January 2025
Center for Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Introduction: Optimising the micronutrient status of women before and during reproduction confers benefits to them and their offspring. Antenatal multiple micronutrient supplements (MMS), given as a daily tablet with nutrients at ~1 recommended dietary allowance (RDA) or adequate intake (AI) reduces adverse birth outcomes. However, at this dosage, MMS may not fully address micronutrient deficiencies in settings with chronically inadequate diets and infection.
View Article and Find Full Text PDFA phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.
Trials
November 2024
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Background: Group A streptococci (Strep A) orStreptococcus pyogenes is a major human pathogen causing an estimated 500,000 deaths worldwide each year. Disease can range from mild pharyngitis to more severe infections, such as necrotizing fasciitis, septicemia, and toxic shock syndrome. Untreated, Strep A infection can lead to the serious post streptococcal pathologies of rheumatic fever/rheumatic heart disease and post-streptococcal glomerulonephritis.
View Article and Find Full Text PDFSubcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit.
Front Med (Lausanne)
August 2024
Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Introduction: Akinetic crisis is a severe deterioration of motor performance occurring in syndromes with pre- or postsynaptic dopaminergic deficit, necessitating effective dopamine replacement therapy. The subcutaneously applicable levodopa derivative foslevodopa represents a new therapeutic option for patients with advanced Parkinson's disease as a continuous therapy. However, its potential role as a parenteral treatment option for akinetic crisis has not been investigated, yet.
View Article and Find Full Text PDFImplementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center.
Infection
December 2024
Department of Medicine, City of Hope, 1500 E Duarte Rd, Duarte, CA, 91010, USA.
Purpose: Beta-lactam allergy (BLA) is associated with increased broad-spectrum antibiotic (Br-ABX) use and worse clinical outcomes. We evaluated our hospital-wide BLA protocol (BLA-P) that used following categories: intolerance, low-risk, and high-risk.
Methods: Hospitalized adult patients with listed BLA during 10/2021-12/2022 were eligible.
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
Zhonghua Jie He He Hu Xi Za Zhi
February 2024
Article Synopsis
- The methacholine challenge test (MCT) is a key method for assessing airway hyperresponsiveness, particularly for diagnosing and treating bronchial asthma.
- A consensus group of experts in respiratory health has updated guidelines on MCT usage, focusing on common clinical issues, preparation, safety, and result interpretation.
- The updated guidelines specify who should undergo the MCT, outline absolute contraindications, and aim to assist healthcare practitioners in effectively using the test for patient assessment and treatment decisions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!